Payment overview · 2025
General Payments
$638.93
39 reported records · 14 companies
Healthcare provider profile · identity verified
Mukesh Jain, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SOUTHAVEN, MS · NPI 1447282991
Verified facts
What the public records show
CMS Open Payments records show Mukesh Jain, MD received $638.93 in general payments during 2025 across 39 reported records.
Lilly USA, LLC accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 257 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 257 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 263 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 267 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $119.77 | 18.8% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $112.97 | 17.7% | 6 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $67.55 | 10.6% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $53.23 | 8.3% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $51.70 | 8.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $34.36 | 5.4% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.05 | 5.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.51 | 5.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $27.39 | 4.3% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.73 | 3.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.40 | 3.7% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $22.68 | 3.5% | 1 | 2025 |
| Pulmonx Corporation | Unresolved — no canonical attribution shown | $19.98 | 3.1% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $15.61 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $638.93 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $119.77 | 12 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $119.77 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $112.97 | 6 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $67.55 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $55.14 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $32.84 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $27.39 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.73 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.40 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $22.68 | 1 | 2025 |
Source payment records
|
|||||
| CHARTIS CATHETER Normalized: chartis catheter |
Device | Pulmonx Corporation | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| PULMONX CHARTIS TABLET CONSOLE Normalized: pulmonx chartis tablet console |
Device | Pulmonx Corporation | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR DELIVERY CATHETER Normalized: zephyr delivery catheter |
Device | Pulmonx Corporation | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| ZEPHYR ENDOBRONCHIAL VALVE Normalized: zephyr endobronchial valve |
Device | Pulmonx Corporation | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.20 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $15.61 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.44 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $13.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 257 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 206 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 263 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 267 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 160 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
206 | 75 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
69 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
66 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
91 | 34 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
257 | 89 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
160 | 54 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
257 | 89 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
263 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
62 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
267 | 56 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 2003 | 268 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1754 | 299 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1643 | 547 |
| Amlodipine Besylate | Amlodipine Besylate | 1281 | 403 |
| Gabapentin | Gabapentin | 1045 | 302 |
| Tizanidine Hcl | Tizanidine Hcl | 1031 | 346 |
| Furosemide | Furosemide | 805 | 276 |
| Potassium Chloride | Potassium Chloride | 766 | 264 |
| Pantoprazole Sodium | Pantoprazole Sodium | 759 | 269 |
| Meloxicam | Meloxicam | 755 | 257 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 731 | 247 |
| Hydralazine Hcl | Hydralazine Hcl | 675 | 229 |
| Omeprazole | Omeprazole | 655 | 214 |
| Clonidine Hcl | Clonidine Hcl | 587 | 193 |
| Losartan Potassium | Losartan Potassium | 531 | 162 |
| Levothyroxine Sodium | Levothyroxine Sodium | 520 | 157 |
| Diclofenac Sodium | Diclofenac Sodium | 471 | 155 |
| Metformin Hcl | Metformin Hcl | 425 | 137 |
| Lisinopril | Lisinopril | 398 | 128 |
| Glimepiride | Glimepiride | 391 | 115 |
| Tramadol Hcl | Tramadol Hcl | 377 | 120 |
| Metoprolol Succinate | Metoprolol Succinate | 374 | 125 |
| Metoprolol Tartrate | Metoprolol Tartrate | 370 | 119 |
| Zolpidem Tartrate | Zolpidem Tartrate | 357 | 67 |
| Pravastatin Sodium | Pravastatin Sodium | 352 | 102 |
| Carvedilol | Carvedilol | 340 | 130 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 326 | 115 |
| Tamsulosin Hcl | Tamsulosin Hcl | 326 | 128 |
| Trazodone Hcl | Trazodone Hcl | 321 | 93 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 303 | 106 |
| Alendronate Sodium | Alendronate Sodium | 297 | 120 |
| Fluticasone Propionate | Fluticasone Propionate | 292 | 121 |
| Ondansetron Hcl | Ondansetron Hcl | 288 | 99 |
| Clopidogrel | Clopidogrel Bisulfate | 279 | 90 |
| Ozempic | Semaglutide | 267 | 56 |
| Pregabalin | Pregabalin | 267 | 59 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 264 | 118 |
| Allopurinol | Allopurinol | 263 | 90 |
| Mounjaro | Tirzepatide | 263 | 43 |
| Jardiance | Empagliflozin | 257 | 89 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 253 | 67 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 252 | 96 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 250 | 77 |
| Alprazolam | Alprazolam | 244 | 53 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 232 | 76 |
| Methylprednisolone | Methylprednisolone | 226 | 171 |
| Ezetimibe | Ezetimibe | 224 | 88 |
| Oxycodone Hcl | Oxycodone Hcl | 223 | 27 |
| Famotidine | Famotidine | 221 | 87 |
| Eliquis | Apixaban | 215 | 75 |
| Linzess | Linaclotide | 206 | 75 |
| Azithromycin | Azithromycin | 189 | 146 |
| Montelukast Sodium | Montelukast Sodium | 186 | 67 |
| Ibuprofen | Ibuprofen | 182 | 64 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 176 | 56 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 172 | 95 |
| Doxycycline Hyclate | Doxycycline Hyclate | 164 | 140 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 160 | 54 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 158 | 126 |
| Methimazole | Methimazole | 158 | 53 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 156 | 45 |
| Simvastatin | Simvastatin | 155 | 48 |
| Citalopram Hbr | Citalopram Hydrobromide | 151 | 42 |
| Atenolol | Atenolol | 146 | 41 |
| Fluconazole | Fluconazole | 145 | 98 |
| Dicyclomine Hcl | Dicyclomine Hcl | 141 | 51 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 141 | 45 |
| Naproxen | Naproxen | 136 | 47 |
| Donepezil Hcl | Donepezil Hcl | 132 | 46 |
| Quetiapine Fumarate | Quetiapine Fumarate | 132 | 28 |
| Lovastatin | Lovastatin | 130 | 35 |
| Temazepam | Temazepam | 129 | 28 |
| Fenofibrate | Fenofibrate | 128 | 43 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 125 | 35 |
| Spironolactone | Spironolactone | 125 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 53 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 121 | 40 |
| Bumetanide | Bumetanide | 114 | 46 |
| Levetiracetam | Levetiracetam | 114 | 42 |
| Amoxicillin | Amoxicillin | 111 | 89 |
| Buspirone Hcl | Buspirone Hcl | 107 | 27 |
| Sertraline Hcl | Sertraline Hcl | 107 | 37 |
| Metformin Hcl Er | Metformin Hcl | 104 | 35 |
| Meclizine Hcl | Meclizine Hcl | 102 | 42 |
| Metoclopramide Hcl | Metoclopramide Hcl | 102 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 100 | 29 |
| Amitriptyline Hcl | Amitriptyline Hcl | 99 | 23 |
| Lidocaine | Lidocaine | 99 | 31 |
| Prednisone | Prednisone | 99 | 43 |
| Colchicine | Colchicine | 96 | 40 |
| Diazepam | Diazepam | 96 | 17 |
| Glipizide | Glipizide | 91 | 29 |
| Ondansetron Odt | Ondansetron | 91 | 49 |
| Symbicort | Budesonide/Formoterol Fumarate | 91 | 34 |
| Fenofibrate | Fenofibrate Nanocrystallized | 90 | 41 |
| Xarelto | Rivaroxaban | 90 | 30 |
| Warfarin Sodium | Warfarin Sodium | 89 | 13 |
| Entresto | Sacubitril/Valsartan | 88 | 35 |
| Labetalol Hcl | Labetalol Hcl | 86 | 29 |
| Lorazepam | Lorazepam | 83 | 23 |
| Januvia | Sitagliptin Phosphate | 82 | 24 |
| Mirtazapine | Mirtazapine | 82 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 32 |
| Valacyclovir | Valacyclovir Hcl | 79 | 33 |
| Cefuroxime | Cefuroxime Axetil | 78 | 66 |
| Paroxetine Hcl | Paroxetine Hcl | 76 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 75 | 25 |
| Promethazine Hcl | Promethazine Hcl | 75 | 21 |
| Megestrol Acetate | Megestrol Acetate | 73 | 35 |
| Memantine Hcl | Memantine Hcl | 73 | 20 |
| Nystatin | Nystatin | 72 | 40 |
| Fenofibrate | Fenofibrate,micronized | 71 | 25 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 71 | 24 |
| Myrbetriq | Mirabegron | 69 | 20 |
| Benazepril Hcl | Benazepril Hcl | 67 | 22 |
| Farxiga | Dapagliflozin Propanediol | 66 | 25 |
| Amiodarone Hcl | Amiodarone Hcl | 64 | 28 |
| Doxazosin Mesylate | Doxazosin Mesylate | 63 | 21 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 63 | 29 |
| Trulicity | Dulaglutide | 62 | 15 |
| Clonidine | Clonidine | 61 | 16 |
| Clonazepam | Clonazepam | 60 | 11 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 59 | 13 |
| Nitroglycerin | Nitroglycerin | 59 | 38 |
| Finasteride | Finasteride | 58 | 22 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 56 | 13 |
| Nifedipine Er | Nifedipine | 55 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 25 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 54 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 40 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 53 | 18 |
| Ketoconazole | Ketoconazole | 52 | 26 |
| Oxybutynin Chloride | Oxybutynin Chloride | 52 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 52 | 21 |
| Testosterone Cypionate | Testosterone Cypionate | 51 | 11 |
| Tradjenta | Linagliptin | 51 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 49 | 18 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 49 | 23 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 48 | 21 |
| Dexlansoprazole Dr | Dexlansoprazole | 47 | 13 |
| Lansoprazole | Lansoprazole | 47 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 42 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 46 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 16 |
| Glipizide Er | Glipizide | 46 | 14 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 46 | 13 |
| Estradiol | Estradiol | 45 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 14 |
| Lactulose | Lactulose | 44 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 44 | 15 |
| Nebivolol Hcl | Nebivolol Hcl | 43 | 12 |
| Valsartan | Valsartan | 43 | 15 |
| Acyclovir | Acyclovir | 42 | 18 |
| Mupirocin | Mupirocin | 42 | 26 |
| Midodrine Hcl | Midodrine Hcl | 41 | 13 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 41 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 41 | suppressed |
| Metolazone | Metolazone | 40 | 13 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 40 | suppressed |
| Dutasteride | Dutasteride | 39 | 16 |
| Synthroid | Levothyroxine Sodium | 39 | suppressed |
| Hydrocortisone | Hydrocortisone | 37 | 20 |
| Topiramate | Topiramate | 37 | 15 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 36 | 11 |
| Propranolol Hcl | Propranolol Hcl | 36 | 11 |
| Rybelsus | Semaglutide | 35 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 35 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 35 | 17 |
| Baclofen | Baclofen | 34 | 15 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | 11 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 34 | suppressed |
| Sotalol | Sotalol Hcl | 34 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 33 | 12 |
| Doxepin Hcl | Doxepin Hcl | 33 | 12 |
| Metronidazole | Metronidazole | 32 | 25 |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 32 | 13 |
| Primidone | Primidone | 32 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Methotrexate | Methotrexate Sodium | 31 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Amlodipine-Valsartan-Hctz | Amlodipine/Valsartan/Hcthiazid | 28 | suppressed |
| Belsomra | Suvorexant | 28 | suppressed |
| Ramipril | Ramipril | 28 | 11 |
| Carisoprodol | Carisoprodol | 27 | suppressed |
| Cephalexin | Cephalexin | 27 | 23 |
| Klor-Con M20 | Potassium Chloride | 27 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | 13 |
| Methocarbamol | Methocarbamol | 26 | 14 |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | 11 |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 25 | 21 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 25 | suppressed |
| Risperidone | Risperidone | 25 | 11 |
| Minoxidil | Minoxidil | 24 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 23 | 14 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Epinephrine | Epinephrine | 22 | 14 |
| Calcitriol | Calcitriol | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | 11 |
| Phenobarbital | Phenobarbital | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | 11 |
| Gemtesa | Vibegron | 20 | suppressed |
| Lacosamide | Lacosamide | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 18 |
| Ibu | Ibuprofen | 19 | suppressed |
| Levemir Flexpen | Insulin Detemir | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 19 |
| Nystop | Nystatin | 19 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | 11 |
| Cilostazol | Cilostazol | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 18 | suppressed |
| Loperamide | Loperamide Hcl | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | 13 |
| Ofloxacin | Ofloxacin | 18 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | 11 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Febuxostat | Febuxostat | 17 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 17 | 13 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Ssd | Silver Sulfadiazine | 15 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Humira Pen | Adalimumab | 14 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 13 |
| Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Copaxone | Glatiramer Acetate | 12 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Isentress | Raltegravir Potassium | 11 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $638.93 · 39 records | Lilly USA, LLC | ACCRUFER, AIRSUPRA, AREXVY, CHARTIS CATHETER, CREON, EVENITY, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, LINZESS, MOUNJARO, OTEZLA, Ohtuvayre, Ozempic, PROLIA, PULMONX CHARTIS TABLET CONSOLE, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, Veozah, XIFAXAN, ZEPBOUND, ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error